\
&
Contact us
\
&
Contact us
The European Innovation Council (EIC) pilot supports researchers and innovators developing breakthrough innovations with the potential to create new markets and boost jobs, growth and prosperity in Europe. It will pilot two new schemes.
I. The EIC Pathfinder pilot (grant only)
II. The EIC Accelerator pilot (grant only and blended finance1)
SME Instrument Close-to-market and projects with a potential to scale up of a single SME established in EU Member States or Horizon 2020 associated countries.
Other Calls
Fast Track to Innovation (FTI) - Close-to-market projects of consortia with three to five entities from at least three different EU Member States or Horizon 2020 associated countries. Industry must participate. Interdisciplinary approaches encouraged.
Other actions
Horizon Prizes - Horizon Prizes boost breakthrough innovation by fostering solutions to challenges which bring major benefits to society.
Support Actions - Help to optimise the impact of EU investment in EIC innovators and innovations; they contribute to building an EIC community and a vision underpinning a possible future EIC.
magali.parent@vlaio.be
+32 2 432 42 42
margot.beereboom@fwo.be
+32 2 550 15 76
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
